<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>

    <!-- Bootstrap CDN -->
    <link rel="stylesheet" href="css/bootstrap.min.css">

    <!-- Main CSS -->
    <link rel="stylesheet" href="css/style.css">

</head>

<body>

    <div class="fixedHeight smlLineHight">
        <div class="right_shape">
            <a href="../page36/index.html" class="cross_icon_close">
                <img src="img/cross_icon.svg" alt="">
            </a>
            <img src="img/right_silver_shape.png" style="zoom: .5;" alt="">
        </div>
        <div class="container_xxl container-xxl p7_px py-5 z_index9">
            <div class="py-5">
                <div class="pt-3">
                    <p class="GothamBold txt_silver refTitle">REFERENCES:</p>
                    <div class="txt_silver GothamBook fs-11">
                        <p class="mb-0">1. Moreau P, et al. N Eng J Med. 2016;374:1621-34</p>
                        <p class="mb-0">2. Hajek R, et al. Future Oncol. 2021; epub ahead of print.</p>
                        <p class="mb-0">3. Terpos E, et al. Ann Hematol. 2020;99:1049-61.</p>
                        <p class="mb-0">4. Avet-Loiseau H, et al. Blood. 2017;130(24):2610-18.</p>
                        <p class="mb-0">5. Chari A, et al. Exp Rev Hematol. 2020;13(4):421-33.</p>
                        <p class="mb-0">6. Ixazomib Philippines Prescribing Information, EU SmPC/21 January 2021/Ixazomib (NINLARO).</p>
                    </div>
                </div>
                <br>
                <div class="txt_silver p7_p0 p7_br_none fs-11">
                    <p class="GothamBold refTitle">CLINICAL STUDY TITLE:</p>
                    <p class="GothamBook">Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.</p>
                    <br>
                    <p class="GothamBold">No. of Patients: <span class="GothamBook">360</span></p>
                    <br>
                    <p class="GothamBook" style="max-width: 1050px;"><span class="GothamBold">Treatment Period:</span> The global, randomized, double-blind, placebo-controlled, phase 3 TOURMALINE-MM1 study enrolled patients from 147 sites in 26 <br>
                        countries between 28 August 2012 and 27May 2014.</p>
                    <br>
                    <p class="GothamBook" style="max-width: 1050px;"><span class="GothamBold">Trial Design:</span> The phase 3 TOURMALINE-MM1 study demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomide-<br> dexamethasone (IRd) compared with placebo-lenalidomide-dexamethasone (placebo-Rd). This pre-planned analysis assessed the efficacy and safety of <br>
                        IRd vs placebo-Rd according to cytogenetic risk, as assessed using fluorescence in situ hybridization. High-risk cytogenetic abnormalities were <br>
                        defined as del(17p), t(4;14), and/or t(14;16); additionally, patients were assessed for 1q21 amplification.</p>
                    <br>
                    <p class="GothamBook" style="max-width: 1050px;"><span class="GothamBold">Clinical Endpoints:</span> The primary end point was PFS; key secondary end points were OS in the intent-to-treat population and OS in patients with del(17p). <br>
                        Other pre-specified secondary end points included overall response rate, rate of complete response (CR) plus very-good-partial response (VGPR), duration <br>
                        of response, time to progression (TTP), PFS in patients with high-risk cytogenetics, and safety.</p>
                    <br>
                    <p class="GothamBook" style="max-width: 1050px;"><span class="GothamBold">Statistical Significance:</span> <br> Of 722 randomized patients, 552hadcytogenetic results; 137 (25%)had high-risk cytogenetic abnormalities and172 (32%)had 1q21 amplification alone. PFS
                        was improved with IRd vs placebo-Rd in both high-risk and standard-risk cytogenetics subgroups: in high-risk patients, the hazard ratio (HR) was 0.543
                        (95% confidence interval [CI], 0.321-0.918; P 5 .021), with median PFS of 21.4 vs 9.7 months; in standard-risk patients, HR was 0.640 (95% CI, 0.462-0.888;
                        P 5 .007), with median PFS of 20.6 vs 15.6 months. This PFS benefit was consistent across subgroups with individual high-risk cytogenetic abnormalities,
                        including patients with del(17p) (HR, 0.596; 95% CI, 0.286-1.243). PFS was also longer with IRd vs placebo-Rd in patients with 1q21 amplification (HR, 0.781;
                        95% CI, 0.492-1.240), and in the “expanded high-risk” group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification (HR,
                        0.664; 95% CI, 0.474-0.928). IRd demonstrated substantial benefit compared with placebo-Rd in relapsed and/or refractory MM (RRMM) patients with
                        high-risk and standard-risk cytogenetics, and improves the poor PFS associated with high-risk cytogenetic abnormalities.</p>
                </div>
            </div>
        </div>
        <div style="height: 80px;"></div>
        <div class="footer_page1 bg-transparent">
            <div class="footer_inner_nav1 bg-transparent footer_inner_nav1_modified_reff">
                <ul class="mb-1 me-1">
                    <li>
                        <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                    </li>
                    <li>
                        <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" class="text-uppercase">pi</a>
                    </li>
                    <li>
                        <a href="#" class="text-uppercase">ref</a>
                    </li>
                </ul>
            </div>
        </div>
    </div>

</body>

</html>